GSK: Liberum upgrades stock
(CercleFinance.com) - Liberum has upgraded its rating on the GSK (GlaxoSmithKline) share from "hold" to "buy," while adjusting its corresponding target price from 18.
40 pounds to 17.30 pounds (32% residual upside potential), with the health group about to celebrate its 20th anniversary in December.
"The last decade has been challenging, but the company enters its twenties with a new management team, fewer product headwinds, and innovative growth drivers in the oncology and vaccine franchises," the broker said.
Therefore, Liberum expects a long-lasting period of growth, which is not reflected in the share's valuation. "Furthermore, GSK is finally preparing to unlock this value through the 2022 Consumer Health spinoff," it added.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
40 pounds to 17.30 pounds (32% residual upside potential), with the health group about to celebrate its 20th anniversary in December.
"The last decade has been challenging, but the company enters its twenties with a new management team, fewer product headwinds, and innovative growth drivers in the oncology and vaccine franchises," the broker said.
Therefore, Liberum expects a long-lasting period of growth, which is not reflected in the share's valuation. "Furthermore, GSK is finally preparing to unlock this value through the 2022 Consumer Health spinoff," it added.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.